World Health Summit: Developing Antibiotics for Children to Achieve SDG3


25 Oct 2020

Title: Developing Antibiotics for Children to Achieve SDG3
Session date: October 25, 2020, 11:00 AM – 12:30 PM
Digital participation: https://worldhealthsummit-org.zoom.us/j/96329253796

Speakers:

  • Prof Sithembiso Velaphi, Associate Professor University of the Witwatersrand and Head of Paediatrics, South Africa
  • Dr Manica Balasegaram, Executive Director, GARDP
  • Dagmar Reitenbach, Head of Division Global Health Federal Ministry of Health, Germany
  • Dr Elmar Nimmesgern, Secretariat Lead, Global R&D AMR Hub
  • Dr Nicholas Adomakoh, Global Medical Affairs Lead, Anti-Infectives, Sandoz
  • Dr Alex Costa, HIV/AIDS Specialist, UNICEF

Overview:
Sepsis, a complication of infection encompassing bloodstream infections, meningitis and pneumonia, is the third most common cause of death among newborns, accounting for 225,000 deaths globally every year. The World Health Organization has called for urgent action to accelerate the development of new antibiotics for bacterial infections, including sepsis, alongside expanded access to antibiotics for newborns and children, in order to facilitate the achievement of Sustainable Development Goal 3: Health and Wellbeing for All.

Addressing the challenge of developing new antibiotics and expanding access to currently available antibiotics for children cannot be solved by one country, company or organization alone. It can only be addressed through a global and multi-sectoral approach. Partnerships between governments, industry, academia and civil society are needed to ensure plans are developed and resources are optimized to accelerate antibiotic research, development and access for children; while in parallel health systems and practice are advanced to bring about sustainable and durable impact.

Join GARDP at the online World Health Summit, for a session discussing the unique challenges of antibiotic research focusing on children and newborns. This will include the progress being made, what can be done in the meantime, and further action required to develop new treatments and ensure expanded access to treatments for children and newborns. The event will also include a discussion of what lessons can be learned from COVID-19 to tackle the pandemic of drug-resistant infections.

DIGITAL PARTICIPATION
Digital participation is free of charge and possible without registration. GARDP’s session can be accessed by clicking here.

 


We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.